ORPHA:168811
Malignant peritoneal mesothelioma
Also known as: Diffuse malignant peritoneal mesothelioma · Primary malignant peritoneal mesothelioma
Publications
1,423
86.6th percentile
Trials
9
Interventional, condition-specific
Researchers
1,018
Distinct authors in sample
Gene link
—
Readiness
3/6
Stages with a signal
Clinical definition (Orphanet)
Malignant peritoneal mesothelioma is a primary peritoneal malignancy occurring in the lining cells (mesothelium) of the peritoneal cavity.
How rare: 1-9 / 1 000 000 — roughly one to nine people per million. In a city the size of Kolkata, perhaps a few dozen.
Cross-references
Joined from Mondo / Orphanet. MeSH labels may enter searches; UMLS / OMIM / NCIT are stored for reference.
- MONDO:0005512
- UMLS:C0346109
- NCIT:C8704
Additional Mondo synonyms (9)
advanced malignant mesothelioma of peritoneum · advanced malignant mesothelioma of the peritoneum · advanced peritoneal malignant mesothelioma · diffuse malignant peritoneal mesothelioma · malignant mesothelioma (disease) of peritoneum · malignant peritoneal mesothelioma, advanced · peritoneal mesothelioma (disease), malignant · peritoneum malignant mesothelioma (disease) · primary malignant peritoneal mesothelioma
Research stages
Trial readiness signals
Where this condition sits on an open-data research pipeline — not how close a treatment is, and not medical advice. Empty stages often mean “not in these databases under this Mondo ID,” not “impossible.”
3/6 stages with a signal
An interventional trial matched this condition name on ClinicalTrials.gov — see trials below.
- Gene identifiedNot found
No GenCC disease–gene assertion in this build
- LiteraturePresent
1,423 matched papers (831 in last 10 years) Source
- Phenotype characterisedPresent
10 HPO annotations (e.g. Abdominal pain; Ascites; Weight loss) Source
- Animal modelNot found
No Alliance genotype “model of” associations via Monarch for these Mondo IDs
- Orphan designationNot found
No FDA or EMA orphan-drug designation matched this disease via UMLS or preferred name Source
- Interventional trialPresent
9 matched on ClinicalTrials.gov (3 recruiting in sample)
Biology
Genes and phenotypes
Gene–disease validity from GenCC, plus phenotypes and animal models joined from Monarch Initiative via Mondo ID — not a clinical diagnosis aid.
Do we know what causes it?
Not yet — the cause hasn't been pinned down in GenCC.
No strong gene–disease assertion joined for this Orphanet entity.
Phenotypes (Monarch / HPO)
10
Associated phenotypes · MONDO:0005512
- Abdominal pain
- Ascites
- Weight loss
- Abnormality of coagulation
- Peritonitis
Showing 5 of 10 — open Monarch for the full list.
Animal models (Monarch / Alliance)
None returned for this Mondo ID. Empty here is not proof that no model organism work exists under another name or gene.
Monarch fetch 2026-07-29
Therapies
Designations, candidates, and chemicals
FDA OOPD and EMA orphan designations, Open Targets clinical candidates, and CTD chemical associations via MyDisease.info. These never change the interventional-trial headline.
Orphan designation (FDA · EMA)
No designation matched this disease via UMLS or preferred name on the FDA OOPD mirror or EMA orphan register. Absence here is not proof that none exists under another wording.
Open Targets candidates
16
Drugs / clinical candidates · MONDO_0005512
- BEVACIZUMAB·phase 2
- CARBOPLATIN·phase 2
- CISPLATIN·phase 2
- DOXORUBICIN·phase 2
- ERLOTINIB HYDROCHLORIDE·phase 2
- GEMCITABINE·phase 2
- OXALIPLATIN·phase 2
- PEMETREXED·phase 2
- SINTILIMAB·phase 2
- TALAZOPARIB·phase 2
- CELECOXIB·phase 1 2
- INTERFERON ALFA-2B·phase 1 2
- PACLITAXEL·phase 1 2
- PEMBROLIZUMAB·phase 1 2
- RINTATOLIMOD·phase 1 2
CTD chemicals (MyDisease.info)
No CTD chemical associations returned for this Mondo ID.
Literature
Is anyone studying this?
1,423
1,423 papers have been published on this condition. That is a real research literature — still far smaller than common diseases (breast cancer: over 700,000 papers). Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=3967) is 59.
1,423 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 59 (publications denominator n=3967).
831 in the last 10 years · high confidence · 86.6th percentile (publications denominator)
Phrase hits: 1,423 · MeSH hits: 0
Who's working on it?
1,018
Distinct author names in 200 sampled papers — named people below.
Who's working on it?
People publishing on this condition (sampled Europe PMC records). Affiliation is the most recent found in that sample.
- 01Li Y21 papers · 2026
Department of Peritoneal Cancer Surgery, Beijing Shijitan Hospital, Capital Medical University, Beijing, 100038, People's Republic of China.
Papers in Europe PMC - 02Kusamura S14 papers · 2026
Peritoneal Malignancy Program, Department of Surgery, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
Papers in Europe PMC - 03Deraco M13 papers · 2026
Peritoneal Malignancy Program, Department of Surgery, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
Papers in Europe PMC - 04Kepenekian V13 papers · 2026
Service de Chirurgie Digestive, Hôpital Lyon Sud, Hospices Civils de Lyon, Pierre-Bénite, France. vahan.kepenekian@chu-lyon.fr.
Papers in Europe PMC - 05Ma R13 papers · 2026
Department of Peritoneal Cancer Surgery, Beijing Shijitan Hospital, Capital Medical University, No. 10 Tieyi Road, Yangfangdian Street, Haidian District, Beijing 100038, China.
Papers in Europe PMC - 06
- 07Su YD12 papers · 2026
Department of Peritoneal Cancer Surgery, Beijing Shijitan Hospital, Capital Medical University, Haidian District, No. 10 Tieyi Road, Yangfangdian Street, Beijing, 100038, China.
Papers in Europe PMC - 08Wu HL12 papers · 2026
Department of Peritoneal Cancer Surgery, Beijing Shijitan Hospital, Peking University Ninth School of Clinical Medicine, Beijing, 100038, China.
Papers in Europe PMC - 09
- 10Yang R11 papers · 2026
Department of Peritoneal Cancer Surgery, Beijing Shijitan Hospital, Capital Medical University, Beijing 100038, China.
Papers in Europe PMC
Clinical research
Is a treatment being tested?
9
interventional trials for this specific condition
9 interventional trials matched this specific condition name; 3 currently recruiting in our sample. 18 trials are registered for peritoneal mesothelioma, the broader category — shown separately because they may or may not enrol this specific subtype.
Data as of 11 September 2026
9 interventional trials — more than 77.2% of diseases in the trials denominator have none at all (5501 of 7126; this disease is at the 92th percentile).
high confidence · 92th percentile (trials denominator)
Recruiting interventional trials
From the matched ClinicalTrials.gov set
9 interventional trials matched after quoted-phrase search and title/condition post-filter.
- NCT06057935·RECRUITING·A Study of Additional Chemotherapy After Surgery for People With Malignant Peritoneal Mesothelioma
Not reviewed·Conditions: Malignant Peritoneal Mesothelioma · Peritoneal Mesothelioma · Mesothelioma · Mesothelioma, Malignant·Matched via name phrase
- NCT06756035·RECRUITING·CT-95 in Advanced Cancers Associated With Mesothelin Expression
Not reviewed·Conditions: Mesothelin-Expressing Tumors · Epithelial Ovarian Cancer · Malignant Pleural Mesothelioma, Advanced · Malignant Peritoneal Mesothelioma, Advanced·Matched via name phrase
- NCT06543069·RECRUITING·Sintilimab, Bevacizumab, Pemetrexed, and Cisplatin for Unresectable MPeM
Not reviewed·Conditions: Malignant Peritoneal Mesothelioma, Advanced·Matched via name phrase
Broader category: peritoneal mesothelioma
18
Interventional trials for the parent category, exclusive of NCT IDs already counted above. Eligibility for this subtype is not guaranteed.
Worth raising with a clinician. How we count trials.
Recruiting under the broader category
- NCT04847063·RECRUITING·Individual Response to Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Treatment of Peritoneal Carcinomatosis From Peritoneal Mesothelioma or Atypical Mesothelial Proliferation or From Ovarian, Colorectal, or Appendiceal Histologies
Not reviewed·Conditions: Peritoneal Mesothelioma · Peritoneal Carcinomatosis · Ovarian Cancer · Gastrointestinal Cancer·Matched via name phrase
- NCT07277413·RECRUITING·A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors
Not reviewed·Conditions: NSCLC Adenocarcinoma · Gastroesophageal Cancer (GC) · Gastric Adenocarcinoma · Adenocarcinoma of Esophagus·Matched via name phrase
- NCT07510815·RECRUITING·Dual-Target MSLN/FAP CAR-NK Cells for Pleural and Peritoneal Mesothelioma
Not reviewed·Conditions: Malignant Pleural Mesotheliomas·Matched via name phrase
- NCT07330271·RECRUITING·PTC-Guided Therapy for Peritoneal Mesothelioma
Not reviewed·Conditions: Peritoneal Mesothelioma·Matched via name phrase
- NCT05001880·RECRUITING·Chemotherapy With or Without Immunotherapy for Peritoneal Mesothelioma
Not reviewed·Conditions: Peritoneal Malignant Mesothelioma·Matched via name phrase
Other registries (secondary)
Broader net from EU CTIS, ISRCTN, and ICTRP when available — deduped against ClinicalTrials.gov IDs already counted above. Dual-model LLM relevance gates what we keep. These rows are not added to the interventional headline.
raw 3 · after dedupe 3 · already on CT.gov 0 · kept 0 · parent 0 · uncertain 3 · dropped 0 · fetched 2026-07-30
Source notes: ictrp: Error: ICTRP public search unavailable (WHO portal is SPA-only; SOAP needs partnership). Tried: https://apps.who.int/tri
No secondary-registry studies passed dual-model relevance for this condition name (after dedupe).
Uncertain / not reviewed (3)
- ctis·2024-516738-36-00·Cancelled·INTERACT MESO: Intraperitoneal Paclitaxel for Patients with Primary Malignant Peritoneal
Mesothelioma – a Phase I/II Dose Escalation and Safety Study
skipped — LLM skipped (--skip-llm)
- ctis·2024-514104-14-00·Expired·TALAMESO : A Three-Cohort Phase II trial to Assess the Efficacy of a Maintenance Treatment with TALAzoparib following First Line Platinum-based Chemotherapy in Pleural or Malignant Peritoneal MESOthelioma Patients
skipped — LLM skipped (--skip-llm)
- ctis·2024-515343-39-00·Cancelled·Phase II multicenter randomized trial evaluating the association of PIPAC and systemic
chemotherapy versus systemic chemotherapy alone as 1st-line treatment of Malignant
Peritoneal Mesothelioma
skipped — LLM skipped (--skip-llm)
Where to find support
Condition-specific patient organisations, when Orphanet lists them, are on the disease’s Orphanet page. We also link umbrella groups that support undiagnosed and ultra-rare families.
Orphanet entry for Malignant peritoneal mesothelioma — check Associations / patient organisations on that page.
India — NPRD
Last verified 2026-07-26This ORPHAcode is not on our curated NPRD list (direct or Mondo-parent match). That does not decide clinical eligibility; families in India should ask a notified Centre of Excellence about current coverage.
Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.
How we counted this
Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored on the overview but are not added to the query string.
"Malignant peritoneal mesothelioma" OR "Diffuse malignant peritoneal mesothelioma" OR "Primary malignant peritoneal mesothelioma" OR "advanced malignant mesothelioma of peritoneum" OR "advanced malignant mesothelioma of the peritoneum" OR "advanced peritoneal malignant mesothelioma" OR "malignant mesothelioma (disease) of peritoneum" OR "malignant mesothelioma (disease) of the peritoneum" OR "malignant peritoneal mesothelioma, advanced" OR "peritoneal mesothelioma (disease), malignant" OR "peritoneum malignant mesothelioma (disease)"
ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):
"Malignant peritoneal mesothelioma" OR "Diffuse malignant peritoneal mesothelioma" OR "Primary malignant peritoneal mesothelioma" OR "advanced malignant mesothelioma of peritoneum" OR "advanced malignant mesothelioma of the peritoneum" OR "advanced peritoneal malignant mesothelioma" OR "malignant mesothelioma (disease) of peritoneum" OR "malignant mesothelioma (disease) of the peritoneum" OR "malignant peritoneal mesothelioma, advanced" OR "peritoneal mesothelioma (disease), malignant" OR "peritoneum malignant mesothelioma (disease)"
Interventional trials matched via: phrase (mesh = registered under a MeSH descriptor no name phrase would catch; recall-expansion = gene / selected parent terms used only for trials).
Study-type breakdown: 9 interventional · 0 observational · 0 expanded access. Only interventional studies enter the trial headline.
Parent-category trials query:
"peritoneal mesothelioma"
Query health: ok — strategies attempted: phrase; with hits: phrase
Run this search on ClinicalTrials.gov
Confidence reasoning
- Preferred label is multi-word and distinctive
- No synonyms dropped by stoplist
- No label/synonym collisions with other diseases in this corpus
Ingested 2026-07-27T08:30:50.819Z
